FDA Approves New Targeted Agent for Acute Myeloid Leukemia

The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.

Source: CancerNetwork - August 1, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news